24 May 2013
Keywords: IBS, Irritable bowel syndrome, Market forecasts, Pipeline, GlobalData
Article | 27 August 2012
Both the current filed status and Phase III pipeline for irritable bowel syndrome (IBS) are sparse. The recent marketed products ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
27 August 2012
23 May 2013
© 2013 thepharmaletter.com